Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Irene Rius Ruiz"'
Autor:
Enrique J. Arenas, Alex Martínez-Sabadell, Irene Rius Ruiz, Macarena Román Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquín Arribas
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Several mechanisms of resistance to T cell-engaging therapies have been described for solid tumors. Here, by using T cell bispecific antibodies and chimeric antigen receptors (CAR) T cells targeting HER2, the authors show that cancer cell intrinsic d
Externí odkaz:
https://doaj.org/article/aa94e03a034246f68048ebc589ddfa65
Autor:
Macarena Román, Irene Rius-Ruiz, Ariadna Grinyó-Escuer, Santiago Duro-Sánchez, Marta Escorihuela, Ekkehard Moessner, Christian Klein, Joaquín Arribas
Redirection of T lymphocytes against tumor-associated or tumor-specific antigens, via bispecifc T cells engagers (BiTEs) or chimeric antigen receptors (CARs), is a successful therapeutic strategy against certain hematologic malignancies. In contrast,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddc3bb6f556382499196a02b7099cc1b
https://doi.org/10.1101/2022.05.20.492812
https://doi.org/10.1101/2022.05.20.492812
Autor:
Alex Martínez-Sabadell, Beatriz Morancho, Irene Rius Ruiz, Macarena Román Alonso, Pablo Ovejero Romero, Marta Escorihuela, Irene Chicote, Hector G. Palmer, Lara Nonell, Mercè Alemany-Chavarria, Christian Klein, Marina Bacac, Joaquín Arribas, Enrique J. Arenas
Publikováno v:
Scientia
Cancer; Antigen; Resistance Cáncer; Antígeno; Resistencia Càncer; Antigen; Resistència Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc127f0012885156478e5e44597d762d
https://pubmed.ncbi.nlm.nih.gov/36261015
https://pubmed.ncbi.nlm.nih.gov/36261015
Autor:
Alex Martínez-Sabadell, Enrique J. Arenas, Irene Rius Ruiz, Macarena Román Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquin Arribas
Publikováno v:
Cancer Research. 82:3970-3970
Elimination of cancer cells by effector immune cells represents the culmination of a complex cascade of events, and disruption of any of those events may result in resistance. T cell-engaging therapies, such as T cell bispecific antibodies (TCBs) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d52e064b0531e78089ad6322b0f0f632
https://doi.org/10.1158/1538-7445.am2022-3970
https://doi.org/10.1158/1538-7445.am2022-3970
Autor:
Iván Pérez-Núñez, Catalina Rozalén, José Ángel Palomeque, Irene Sangrador, Mariona Dalmau, Laura Comerma, Anna Hernández-Prat, David Casadevall, Silvia Menendez, Daniel Dan Liu, Minhong Shen, Jordi Berenguer, Irene Rius Ruiz, Raul Peña, José Carlos Montañés, M. Mar Albà, Sarah Bonnin, Julia Ponomarenko, Roger R. Gomis, Juan Miguel Cejalvo, Sonia Servitja, Diego M. Marzese, Lluis Morey, Leonie Voorwerk, Joaquín Arribas, Begoña Bermejo, Marleen Kok, Lajos Pusztai, Yibin Kang, Joan Albanell, Toni Celià-Terrassa
Publikováno v:
Nature cancer. 3(3)
Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy is poorly understood. Here we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12fd4faf643be656cd7dd5e7b67dcba
https://pubmed.ncbi.nlm.nih.gov/35301507
https://pubmed.ncbi.nlm.nih.gov/35301507
Autor:
Joaquín Arribas, Alena Gros, Enrique Javier Arenas Lahuerta, Antonio Luque, Irene Rius Ruiz, Carlos Alberto Fajardo, Macarena Román Alonso, Alex Martínez-Sabadell, Christian Klein, Marta Escorihuela
Publikováno v:
Cancer Research. 81:1690-1690
Introduction: Elimination of cancer cells by effector immune cells represents the culmination of a complex cascade of events, and disruption of any of those events may result in resistance. T cell-engaging therapies, such as T cell bispecific antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b72ecc37064a2d7c5eb3323a41a04bb
https://doi.org/10.1158/1538-7445.am2021-1690
https://doi.org/10.1158/1538-7445.am2021-1690
Autor:
John Winslow, Isabel T. Rubio, Johannes Sam, Vicente Peg, Violeta Serra, Ahmed Chenna, Pablo Umana, Cristina Saura, Paolo Nuciforo, Jeff Sperinde, Enrique J. Arenas, Rocio Vicario, Joaquín Arribas, Josep Tabernero, Weidong Huang, José Baselga, Santiago Escrivá-de-Romaní, Javier Cortes, Christian Klein, Sylvia Herter, Joan Seoane, Jitka Somandin, Roberta Fasani, Irene Rius Ruiz, Oliver Ast, Marta Escorihuela, Ismael Varela, Marina Bacac, Joan Albanell, Isabel Cuartas, Águeda Martinez Barriocanal, Beatriz Morancho, Anne Freimoser-Grundschober, Cristina Bernadó Morales, Antonio Luque, Maurizio Scaltriti
Publikováno v:
Science Translational Medicine. 10
T cell bispecific antibodies (TCBs) are engineered molecules that include, within a single entity, binding sites to the T cell receptor and to tumor-associated or tumor-specific antigens. The receptor tyrosine kinase HER2 is a tumor-associated antige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5afd191e7518caf55dcd9c937ab0adde
https://doi.org/10.1126/scitranslmed.aat1445
https://doi.org/10.1126/scitranslmed.aat1445
Autor:
Ismael Varela, Rocio Vicario, Johannes Sam, J. Baselga, Marina Bacac, Isabel T. Rubio, Jeff Sperinde, Cristina Saura, Jitka Somandin, Weidong Huang, Violeta Serra, Águeda Martinez Barriocanal, Maurizio Scaltriti, Beatriz Morancho, Antonio Luque, Oliver Ast, Ahmed Chenna, Irene Rius Ruiz, Christian Klein, Pablo Umana, John Winslow, Javier Cortes, Paolo Nuciforo, Sylvia Herter, Vicente Peg, Joaquín Arribas, Cristina Bernadó Morales, Anne Freimoser-Grundscholber, Josep Tabernero, Santiago Escrivá, Marta Escorihuela, Roberta Fasani
Publikováno v:
Cancer Research. 78:LB-292
T cell bispecific antibodies (TCBs) are engineered molecules that include, within a single entity, binding sites to the T cell receptor and to a tumor-specific or a tumor-associated antigen. The receptor tyrosine kinase HER2 is a tumor-associated ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a67b686fc1b2e2e61dadafb46139313
https://doi.org/10.1158/1538-7445.am2018-lb-292
https://doi.org/10.1158/1538-7445.am2018-lb-292
Publikováno v:
Sokol, M, Wabl, M, Rius Ruiz, I & Pedersen, F S 2014, ' Novel Principles of Gamma-Retroviral Insertional Transcription Activation in Murine Leukemia Virus-induced End-stage Tumors ', Retrovirology, vol. 11, no. 36 . https://doi.org/10.1186/1742-4690-11-36
Retrovirology
Retrovirology
BackgroundInsertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the assignment of mouse genes to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9713fb665b9318c41d3771a5972c5047
https://doi.org/10.1186/1742-4690-11-36
https://doi.org/10.1186/1742-4690-11-36